Outset Medical, Inc.
Outset Medical is a medical technology company that develops Tablo, an FDA-cleared hemodialysis system for hospitals, clinics and home use. The system combines a compact console with integrated water purification and on-demand dialysate production, disposable cartridges, software and wireless connectivity. Its data platforms support remote device and treatment monitoring, patient analytics, training and clinical recordkeeping. Outset sells Tablo consoles, cartridges and other consumables, and supports providers with services including training, field service, clinical expertise, data analytics and electronic health record integration. It works with hospitals to establish and maintain in-house dialysis services and serves acute, post-acute and home-care settings. Outset manufactures consoles and most cartridges at its facility in Tijuana, Mexico, and its headquarters are in San Jose, California.
No SEC Form 4 filings for $OM in the last 30 days.
See all $OM insider activity →Osisko Metals closed a C$25.0M private placement, issuing 9.46M flow-through shares at C$2.64 each. Agnico Eagle Mines and Hudbay Minerals bought all shares. TSX acceptance is pending.
Osisko Metals reported new drill results from its Gaspé Copper project, including 94.4m at 1.47% copper and 121m at 0.71% copper in a newly identified porphyry. The results aim to expand mineralization and convert inferred resources to measured and indicated categories.
Leonard Braden Michael purchased 244,909 indirectly-held shares of Outset Medical, Inc. (OM) at an average of $3.55 ($3.53–$3.88, $0.87M total) across 2 trades over 2026-10-01 to 2026-10-02.
Over the past 7 days, AlphAI's AI scored 1 news story mentioning OM (Outset Medical, Inc.). Coverage has been balanced: 0 bullish, 1 neutral, and 0 bearish.
Recent OM coverage spans corporate actions, financial news and earnings.
The financing likely supports near-term exploration funding but can pressure the stock via dilution expectations until TSX acceptance and use-of-proceeds clarity.
The drill intercepts could increase the resource base and improve the project's economics.
Insider purchase signals confidence and may support the stock price.
No rating change, limited impact.
Departure of a senior legal officer may cause short‑term uncertainty but no immediate financial impact.
AlphAI scores every news story that mentions OM with an AI model for sentiment and relevance, and aggregates insider trades from Outset Medical, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Osisko Metals closed a C$25.0M private placement, issuing 9.46M flow-through shares at C$2.64 each. Agnico Eagle Mines and Hudbay Minerals bought all shares. TSX acceptance is pending.
4 min readOsisko Metals reported new drill results from its Gaspé Copper project, including 94.4m at 1.47% copper and 121m at 0.71% copper in a newly identified porphyry. The results aim to expand mineralization and convert inferred resources to measured and indicated categories.
1 min readLeonard Braden Michael purchased 244,909 indirectly-held shares of Outset Medical, Inc. (OM) at an average of $3.55 ($3.53–$3.88, $0.87M total) across 2 trades over 2026-10-01 to 2026-10-02.
1 min readAnalysts updated ratings and price targets for Canadian companies. Aya Gold & Silver (AYA:CA) saw a target raise to $56.00. Banyan Gold (BYN:CA) initiated with a $3.00 target. D2L (DTOL:CA) was downgraded to Neutral. Empire Company (EMP.A:CA) had mixed target adjustments. Groupe Dynamite (GRGD:CA) received varied target changes. Transat A.T. (TRZ:CA) saw multiple target cuts.
2 min readOutset Medical, Inc. (OM) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 27, 2026, John Brottem informed Outset Medical, Inc. (the “Company”) of his decision to depart from the Company a
1 min readOutset Medical (OM) reported Q2 2026 revenue of $31.6 million, up 1% year over year and 14% sequentially. Console revenue was $9.5 million, up 6% YoY, while product revenue fell 5% to $21.9 million. Non-GAAP gross margin was 42.2%. Cash and investments were $151 million. Full-year revenue guidance is $125 million to $130 million.
6 min readOutset Medical, Inc. (OM) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Outset Medical Reports Second Quarter 2026 Results San Jose, CA – August 6, 2026 – Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to improve clinical outcomes in dialysis with less cost and complexity, today
6 min readBlackRock, Inc. filed an amended Schedule 13G for Outset Medical, Inc., reporting beneficial ownership of 365,556 shares of Outset Medical common stock, or 2.0% of the outstanding class. BlackRock reported sole voting and sole dispositive power over the shares, with no shared voting or dispositive power.
2 min readNational Bank Financial analysts revised precious-metals and copper forecasts ahead of Q2 earnings, citing realized gold at $4,508/oz and silver at $73/oz, and copper at $5.82/lb. They cut 2026 gold and silver assumptions and adjusted target prices for multiple miners, generally lower. TD Cowen upgraded First Quantum Minerals on a likely Cobre Panama restart by year-end.
7 min readOsisko Metals (TSX: OM) said Glencore Canada converted its US$25 million senior secured convertible debenture into 88,962,500 units at C$0.40 per unit, plus interest conversion into 6,862,444 units at C$1.58 per unit. Glencore Canada also exercised warrants cashlessly, issuing 32,301,860 shares. TSX approval remains pending.
3 min read
